Nucleotide excision repair (NER) orchestrates the repair of helix distorting DNA damage, induced by both ultraviolet radiation (UVR) and cisplatin. There is evidence that the global genome repair (GGR) arm of NER is dysfunctional in melanoma and it is known to have limited induction in melanoma cell lines after cisplatin treatment. The aims of this study were to examine mRNA transcript levels of regulators of GGR and to investigate the downstream effect on global transcript expression in melanoma cell lines after cisplatin treatment and in melanoma tumours. The GGR regulators, BRCA1 and PCNA, were induced in melanocytes after cisplatin, but not in melanoma cell lines. Transcripts associated with BRCA1, BRCA2, ATM and CHEK2 showed altered expression in melanoma cell lines after cisplatin treatment. In melanoma tumour tissue BRCA1 transcript expression correlated with poor survival and XPB expression correlated with solar elastosis levels. Taken together, these findings provide evidence of the mechanisms underlying NER deficiency in melanoma.
References
[1]
Friedberg EC (2001) How nucleotide excision repair protects against cancer. Nature Reviews Cancer 1: 22–33.
[2]
Glover D, Glick JH, Weiler C, Fox K, Guerry D (1987) WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 5: 574–578.
[3]
Eastman A (1985) Interstrand cross-links and sequence specificity in the reaction of cis-dichloro(ethylenediamine) platinum (II) with DNA. Biochemistry 24: 5027–5032.
[4]
Monjardet-Bas V, Chottard JC, Kozelka J (2002) Fast interstrand cross-linking of cisplatin-DNA monoadducts compared with intrastrand chelation: a kinetic study using hairpin-stabilized duplex oligonucleotides. Chemistry 8: 1144–1150.
[5]
Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265–7279.
[6]
Sugasawa K (2010) Regulation of damage recognition in mammalian global genomic nucleotide excision repair. Mutat Res 685: 29–37.
[7]
Nouspikel T (2009) DNA repair in mammalian cells: Nucleotide excision repair: variations on versatillty. Cellular and Molecular Life Sciences 66: 994–1009.
[8]
Marini F, Nardo T, Giannattasio M, Minuzzo M, Stefanini M, et al. (2006) DNA nucleotide excision repair-dependant signaling to checkpoint activation. Proceedings of the National Academy of Sciences of the United States of America 103: 17325–17330.
[9]
Bowden NA, Ashton KA, Avery-Kiejda KA, Zhang XD, Hersey P, et al. (2010) Nucleotide excision repair gene expression after cisplation treatment in melanoma. Cancer Research 70: 7905–7917.
[10]
Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, et al. (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463: 191–196.
[11]
Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, et al. (2012) Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485: 502–506.
[12]
Gaddameedhi S, Kemp MG, Reardon JT, Shields JM, Smith-Roe SL, et al. (2010) Similar nucleotide excision repair capacity in melanocytes and melanoma cells. Cancer Research 70: 4922–4930.
[13]
Wang HT, Choi B, Tang MS (2010) Melanocytes are deficient in repair of oxidative DNA damage and UV-induced photoproducts. Proceedings of the National Academy of Sciences of the United States of America 107: 12180–12185.
[14]
Avery-Kiejda KA, Zhang XD, Adams L, Scott RJ, Vojtesek B, et al. (2008) Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clinical Cancer Research 14: 1659–1668.
[15]
Franco AV, Zhang XD, Van Berkel E, Sanders JE, Zhang XY, et al. (2001) The role of NF-kB in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. Journal of Immunology 166: 5337–5345.
[16]
Thomas WD, Hersey P (1998) TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. The Journal of Immunology 161: 2195–2200.
[17]
Zhang XD, Franco A, Myers K, Gray C, Nguyen T, et al. (1999) Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 59: 2747–2753.
[18]
Bowden NA, Weidenhofer J, Scott RJ, Schall U, Todd J, et al. (2006) Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. Schizophrenia Research 82: 175–183.
[19]
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 102: 15545–15550.
[20]
Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, et al. (2010) Toll-like receptor (TLR) and nucleosome-binding oligodimerization domain (NOD) gene polymorphisms and endometrial cancer risk. BMC Cancer 10: 382.
[21]
Fitch ME, Cross IV, Ford JM (2003) p53 responsive nucelotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation-induced DNA damage, in vivo. Carcinogenesis 24: 843–850.
[22]
Balch CM, Soong S-J, Gershenwald JE, Thompson JF, Reintgen DS, et al. (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. Journal of Clinical Oncology 19: 3622–3634.
[23]
Banks D, Wu W, Higa LA, Gavrilova N, Quan J, et al. (2006) L2DTL/CDT2 and PCNA interact with p53 and regulate p53 polyubiquitination and protein stability through MDM2 nd CUL4A/DDB1 complexes. Cell Cycle 5: 1719–1729.
[24]
Higa LA, Banks D, Wu M, Kobayashi R, Sun H, et al. (2006) L2DTL/CDT2 interacts with the CUL4/DDB1 complex and PCNA and regulates CDT1 proteolysis in response to DNA damage. Cell Cycle 5: 1675–1680.
[25]
Hartman AR, Ford JM (2002) BRCA1 induces DNA damage recognition factors and enhances nucelotide excision repair. Nature Genetics 32: 180–184.
[26]
Navaraj A, Mori T, El-Deiry WS (2005) Cooperation between BRCA1 and p53 in repair of cyclobutane pyrimidine dimers. Cancer Biology & Therapy 12: 1409–1414.
[27]
Chen Z, Yang J, Wang G, Song B, Li J, et al. (2007) Attenuated expression of xeroderma pigmentosum group C is associated with critical events in human bladder cancer carcinogenesis and progression. Cancer Research 67: 4578–4585.
[28]
Wang G, Chuang L, XZhang X, Colton S, Dombowski A, et al. (2004) The initiative role of XPC protein in cisplatin DNA damaging treatment-mediated cell cycle regulation. Nucleic Acids Res 32: 2231–2240.
[29]
Wang G, Dombowski A, Chuang L, Xu XS (2004) The involvement of XPC protein in the cisplatin DNA damaging treatment-mediated cellular response. Cell Research 14: 303–314.
[30]
Stoyanova T, Roy N, Kopanja D, Bagchi S, Raychaudhuri P (2009) DDB2 decides cell fate following DNA damage. Proc Natl Acad Sci U S A 106: 10690–10695.
[31]
Hwang BJ, Ford JM, Hanawalt PC, Chu G (1999) Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genome repair. Proceedings of the National Academy of Sciences of the United States of America 96: 424–428.
[32]
Adimoolam S, Ford JM (2002) p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proceedings of the National Academy of Sciences of the United States of America 99: 12985–12990.
[33]
Jewell R, Conway C, Mitra A, Randerson-Moor J, Lobo S, et al. (2010) Patterns of Expression of DNA Repair Genes and Relapse From Melanoma. Clinical Cancer Research 16: 5211–5221.
[34]
Kaufmann WK, Nevis KR, Qu P, Ibrahim JG, Zhou T, et al. (2008) Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression. J Invest Dermatol 128: 175–187.
[35]
Cleaver JE (2005) Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nature Reviews Cancer 5: 564–573.
[36]
Onken MD, Ehlers JP, Worley LA, Makita J, Yokota Y, et al. (2006) Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Research 66: 4602–4609.
[37]
DeBiasi RL, Clarke P, Meintzer S, Jotte R, Kleinschmidt-Demasters BK, et al. (2003) Reovirus-induced alteration in expression of apoptosis and DNA repair genes with potential roles in viral pathogenesis. Journal of Virology 77: 8934–8947.
[38]
Enk CD, Jacob-Hirsch J, Gal H, Verbovetski I, Amariglio N, et al. (2006) The UVB-induced gene expression profile of human epidermis in vivo is different from that of cultured keratinocytes. Oncogene 25: 2601–2614.
[39]
Perez CA, Ott J, Mays DJ, Pietenpol JA (2007) p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm. Oncogene 26: 7363–7370.
[40]
Hollmann CA, Owens T, Nalbantoglu J, Hudson TJ, Sladek R (2006) Constitutive activation of extracellular signal-regulated kinase predisposes diffuse large B-cell lymphoma cell lines to CD40-mediated cell death. Cancer Research 66: 3550–3557.
[41]
Pujana MA, Han JD, Starita LM, Stevens KN, Tewari M, et al. (2007) Network modeling links breast cancer susceptibility and centrosome dysfunction. Nature Genetics 39: 1338–1349.
[42]
da Costa RM, Riou L, Paquola A, Menck CF, Sarasin A (2005) Transcriptional profiles of unirradiated or UV-irradiated human cells expressing either the cancer-prone XPB/CS allele or the noncancer-prone XPB/TTD allele. Oncogene 24: 1359–1374.
[43]
Gentile M, Latonen L, Laiho M (2003) Cell cycle arrest and apoptosis provoked by UV radiation-induced DNA damage are transcriptionally highly divergent responses. Nucleic Acids Research 31: 4779–4790.
[44]
Dazard JE, Gal H, Amariglio N, Rechavi G, Domany E, et al. (2003) Genome-wide comparison of human keratinocyte and squamous cell carcinoma responses to UVB irradiation: implications for skin and epithelial cancer. Oncogene 22: 2993–3006.
[45]
Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nature Genetics 40: 499–507.
[46]
Matthews L, Gopinath G, Gillespie M, Caudy M, Croft D, et al. (2009) Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Research 37: D619–622.
